XML 27 R13.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Shareholders' Equity (Deficit): | 12 Months Ended
--- | ---
Dec. 28, 2024
Shareholders' Equity (Deficit): |
Shareholders' Equity (Deficit): | 6. Shareholders’ Equity (Deficit): Dividends ​ In 2024, the Company declared and paid quarterly cash dividends totaling $3.50 per share ($12.3 million) and a $7.50 per share special cash dividend. The special dividend paid in 2024 totaled $26.5 million and was paid by cash on hand. ​ In 2023, the Company declared and paid quarterly cash dividends totaling $3.10 per share ($10.8 million) and a $9.40 per share special cash dividend. The special dividend paid in 2023 totaled $32.9 million and was paid by cash on hand. ​ In 2022, the Company declared and paid quarterly cash dividends totaling $2.55 per share ($8.9 million) and a $3.00 per share special cash dividend. The special dividend paid in 2022 totaled $10.4 million and was paid by cash on hand. ​ Repurchase of Common Stock In 2022, the Company purchased 226,165 shares of our common stock for an aggregate purchase price of $49.1 million. ​ Under the Board of Directors’ authorization, as of December 28, 2024 the Company has the ability to repurchase an additional 78,600 shares of its common stock. Repurchases may be made from time to time at prevailing prices, subject to certain restrictions on volume, pricing and timing. ​ Stock Option Plans and Stock-Based Compensation The Company had authorized up to 700,000 shares of common stock for granting either nonqualified or incentive stock options to officers and key employees under the Company’s 2010 Stock Option Plan (the “2010 Plan”). The 2010 Plan expired on February 24, 2020. The Company had also sponsored a Stock Option Plan for Nonemployee Directors (the “Nonemployee Directors Plan”), which had reserved a total of 350,000 shares for issuance to directors of the Company who are not employees. ​ At the April 29, 2020 Annual Shareholders Meeting, the Company’s shareholders approved a new stock option plan, the 2020 Stock Option Plan (the “2020 Plan”). The 2020 Plan (as described more completely in the Company’s definitive Proxy Statement filed with the United States Securities and Exchange Commission on March 10, 2020) provides for the issuance of up to 100,000 shares of common stock plus (i) the number of common stock authorized and unissued under the 2010 Plan (as of April 29, 2020, 125,465 shares), and (ii) the number of shares of common stock authorized and unissued under the Nonemployee Director Plan (as of April 29, 2020, 24,500 shares) in the form of either nonqualified or incentive stock option grants. At the April 24, 2024 Annual Shareholders meeting, the Company’s shareholders approved an increase in the number of common stock available for granting either nonqualified or incentive stock options to officers and key employees under the Company’s 2020 Stock Option Plan (the “2020 Plan”) by 100,000 shares. Participants in the 2020 Plan may include employees, officers, directors, consultants and advisors of the Company. ​ Grants under the 2020 Plan are (as they were under the 2010 Plan and Nonemployee Directors Plan) made by the Compensation Committee of the Board of Directors at a price of not less than 100% of the fair market value on the date of grant. If an incentive stock option is granted to an individual who owns more than 10% of the voting rights of the Company’s common stock, the option exercise price may not be less than 110% of the fair market value on the date of grant. The term of the options may not exceed 10 years, except in the case of nonqualified stock options, whereby the terms are established by the Compensation Committee. Options may be exercisable in whole or in installments, as determined by the Compensation Committee. ​ Stock option activity under the 2010 Plan, 2020 Plan and Nonemployee Directors Plan (collectively, the “Option Plans”) as of December 28, 2024 was as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | ​ | ​ |  | Weighted Average |  | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Remaining | ​ | ​ | ​
​ | ​ | Number of | ​ | Weighted Average | ​ | Contractual Life | ​ | ​ | ​
​ | ​ | Shares | ​ | Exercise Price | ​ | (years) | ​ | Intrinsic Value
Outstanding, December 25, 2021 |  | 355,621 | ​ | $ | 146.03 |  | ​ | ​ | ​ | ​
Granted |  | 62,540 | ​ | ​ | 217.03 | ​ | ​ | ​ | ​ | ​
Exercised |  | (50,032) | ​ | ​ | 94.97 | ​ | ​ | ​ | ​ | ​
Forfeited | ​ | (6,501) | ​ | ​ | 183.28 | ​ | ​ | ​ | ​ | ​
Outstanding, December 31, 2022 |  | 361,628 | ​ | ​ | 164.70 |  | ​ | ​ | ​ | ​
Granted |  | 21,320 | ​ | ​ | 328.68 | ​ | ​ | ​ | ​ | ​
Exercised |  | (37,304) | ​ | ​ | 107.49 | ​ | ​ | ​ | ​ | ​
Forfeited | ​ | (3,752) | ​ | ​ | 204.26 | ​ | ​ | ​ | ​ | ​
Outstanding, December 30, 2023 |  | 341,892 | ​ | ​ | 180.73 | ​ | ​ | ​ | ​ | ​
Granted |  | 25,300 | ​ | ​ | 377.63 | ​ | ​ | ​ | ​ | ​
Exercised |  | (42,767) | ​ | ​ | 117.70 | ​ | ​ | ​ | ​ | ​
Forfeited |  | (4,581) | ​ | ​ | 239.61 | ​ | ​ | ​ | ​ | ​
Outstanding, December 28, 2024 |  | 319,844 | ​ | $ | 203.89 | ​ | 5.72 | ​ | $ | 61,841,500
Exercisable, December 28, 2024 |  | 233,931 | ​ | $ | 173.68 | ​ | 4.82 | ​ | $ | 52,073,200
​ The fair value of options granted under the Option Plans during 2024, 2023 and 2022 were estimated on the date of the grant using the Black-Scholes option pricing model with the following weighted average assumptions and results: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Year Ended |
​ |  | December 28, 2024 | ​ | December 30, 2023 |  | December 31, 2022 |
Risk free interest rate |  | ​ | 4.34 | % | ​ | 3.88 | % | ​ | 3.15 | %
Expected life (years) |  | ​ | 6 | ​ | ​ | 6 | ​ | ​ | 6 | ​
Expected volatility |  | ​ | 29.13 | % | ​ | 28.10 | % | ​ | 27.58 | %
Dividend yield |  | ​ | 2.84 | % | ​ | 2.94 | % | ​ | 4.29 | %
Option fair value | ​ | $ | 98.64 | ​ | $ | 79.88 | ​ | $ | 40.59 | ​
​ The total intrinsic value of options exercised during 2024, 2023 and 2022 was $11.3 million, $9.2 million and $6.6 million, respectively. The total fair value of shares vested during 2024, 2023 and 2022 was $11.1 million, $11.7 million and $10.9 million, respectively. ​ All unexercised options at December 28, 2024 have an exercise price equal to the fair market value on the date of the grant. ​ Compensation expense of $1,988,000, $1,952,400 and $1,652,400 relating to the vested portion of the fair value of stock options granted was expensed to “Selling, General and Administrative Expenses” in 2024, 2023 and 2022, respectively. As of December 28, 2024, the Company had $6.6 million of total unrecognized compensation expense related to stock options that is expected to be recognized over the remaining weighted average vesting period of approximately 2.2 years.

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContent Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContent + Details
Name: | us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration